NLS Pharmaceutics Amends Warrant Agreement
Ticker: NCEL · Form: 6-K · Filed: Sep 17, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Sep 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: warrants, amendment, shares
TL;DR
NLS Pharma amended warrants for 6.9M shares with an investor on Sept 16.
AI Summary
On September 16, 2024, NLS Pharmaceutics Ltd. entered into a warrant amendment agreement with an institutional investor. This amendment modifies warrants previously issued to purchase up to 6,913,462 common shares of the company.
Why It Matters
This amendment could impact the potential dilution of NLS Pharmaceutics' common shares and the financial obligations related to these warrants.
Risk Assessment
Risk Level: low — The filing is a routine amendment to existing warrants and does not appear to involve new financing or significant operational changes.
Key Numbers
- 6,913,462 — Common Shares (Maximum number of shares issuable upon exercise of the amended warrants.)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Filer and party to the agreement
- September 16, 2024 (date) — Date of the warrant amendment agreement
- 6,913,462 (dollar_amount) — Number of common shares subject to the warrants
FAQ
What specific terms of the warrants were amended?
The filing states that the amendment makes 'certain' changes but does not specify the exact nature of these changes in the provided text.
Who is the institutional investor party to the amendment?
The filing refers to the counterparty as 'a certain institutional investor' but does not disclose their specific name.
What is the exercise price of the Common Warrants?
The provided text of the 6-K filing does not mention the exercise price of the Common Warrants.
When were the original warrants issued?
The filing does not specify the original issuance date of the warrants being amended.
Does the amendment affect the expiration date of the warrants?
The provided text does not detail whether the amendment impacts the expiration date of the warrants.
Filing Stats: 632 words · 3 min read · ~2 pages · Grade level 14 · Accepted 2024-09-16 18:07:11
Filing Documents
- ea0214740-6k_nlspharma.htm (6-K) — 17KB
- ea021474001ex10-1_nlspharma.htm (EX-10.1) — 46KB
- ea021474001ex10-2_nlspharma.htm (EX-10.2) — 80KB
- 0001213900-24-079063.txt ( ) — 144KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: September 16, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2